Lonza keeps adding on as it looks to beef up biologics offering, tacking on nearly $1B in expansions in EU, US
Amid a flurry of expansion activity, CDMO Lonza is continuing to beef up its manufacturing plants both in its native Switzerland and in the US. The newest plan? A $935 million outlay to build new sites in Visp and Portsmouth, NH, to help grow the company’s biologics portfolio.
The Swiss plant — which will absorb the vast majority of the new funds — will house six 20,000-liter bioreactors as part of a 90,000-plus-square-foot footprint. The site will be designed to optimize energy and water efficiency and cost about $714 million, Lonza said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.